Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

Literature DB >> 17634858

Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

Frédéric Thibault, Bertrand Billemont, Olivier Rixe.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2007 PMID： 17634858 DOI： 10.1007/s11060-007-9449-5

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

× No keyword cloud information.

5 in total

1. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.

Authors: Nancy D Doolittle; Lauren E Abrey; W Archie Bleyer; Steven Brem; Thomas P Davis; Paula Dore-Duffy; Lester R Drewes; Walter A Hall; John M Hoffman; Agnieszka Korfel; Robert Martuza; Leslie L Muldoon; David Peereboom; Darryl R Peterson; Samuel D Rabkin; Quentin Smith; Glen H J Stevens; Edward A Neuwelt
Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

Review 3. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

Authors: Brian I Rini; Eric J Small
Journal: J Clin Oncol Date: 2004-11-08 Impact factor: 44.544

4. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.

Authors: Z G Zhang; L Zhang; Q Jiang; R Zhang; K Davies; C Powers; N v Bruggen; M Chopp
Journal: J Clin Invest Date: 2000-10 Impact factor: 14.808

Review 5. Current therapeutic approaches in patients with brain metastases.

Authors: Kevin H Peacock; Glenn J Lesser
Journal: Curr Treat Options Oncol Date: 2006-11

5 in total

9 in total

1. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Authors: David A Reardon; James J Vredenburgh; April Coan; Annick Desjardins; Katherine B Peters; Sridharan Gururangan; Sith Sathornsumetee; Jeremy N Rich; James E Herndon; Henry S Friedman
Journal: J Neurooncol Date: 2011-07-09 Impact factor: 4.130

2. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

Authors: Steven G Dubois; Suzanne Shusterman; Ashish M Ingle; Charlotte H Ahern; Joel M Reid; Bing Wu; Sylvain Baruchel; Julia Glade-Bender; Percy Ivy; Holcombe E Grier; Peter C Adamson; Susan M Blaney
Journal: Clin Cancer Res Date: 2011-06-20 Impact factor: 12.531

9. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression.

Authors: L Wyler; C U Napoli; B Ingold; T Sulser; M Heikenwälder; P Schraml; H Moch
Journal: Br J Cancer Date: 2013-12-10 Impact factor: 7.640

9 in total

Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

1. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Review 3. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

4. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.

Review 5. Current therapeutic approaches in patients with brain metastases.

1. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

2. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

3. Progression of intramedullary metastasis during perioperative cessation of sunitinib.

Review 4. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

5. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

Review 6. Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Review 7. Sunitinib Possible Sex-Divergent Therapeutic Outcomes.

8. Contribution of case reports to brain metastases research: systematic review and analysis of pattern of citation.

9. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression.